Product image of Natriumfluorid (F-18) Life Radiopharma (Sodium Fluoride (18f)) supplied by GNH India

Natriumfluorid (F-18) Life Radiopharma

Active Ingredient:
Sodium Fluoride (18f)
Origin:
EU

Natriumfluorid (F-18) Life Radiopharma (Sodium Fluoride (18f))

Sodium fluoride (18F), the active ingredient in Natriumfluorid (F-18) Life Radiopharma, is a radiopharmaceutical presented as a solution for injection for intravenous use. It enables PET imaging of bone turnover, aiding detection of skeletal metastases and evaluation of bone metabolism in oncology patients.

GNH India supplies Natriumfluorid (F-18) Life Radiopharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and clinics worldwide. The company adheres to EU GMP standards and provides regulatory documentation for cross‑border procurement, ensuring timely delivery and quality assurance.

Manufacturer / TM Owner

Alliance Medical Rp Berlin Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Natriumfluorid (F-18) Life Radiopharma is used in PET imaging of the skeletal system to assess bone turnover and metastatic disease.

  • Skeletal metastases detection: enables visualization of metastatic lesions in bone.
  • Bone metabolism evaluation: assesses turnover rates in various bone disorders.
  • Cancer staging: assists in determining the extent of bone involvement in oncologic patients.

How It Works

  • After intravenous administration, the fluoride ion from Sodium fluoride (18F) rapidly incorporates into the hydroxyapatite matrix of bone, replacing hydroxyl groups. The incorporated 18F emits positrons, which are detected by PET scanners, providing a quantitative image of bone remodeling activity and allowing identification of areas with increased osteoblastic activity such as metastatic lesions.

Side Effects

Adverse reactions are generally mild and related to the injection or radiation exposure.

Common Side Effects

  • Injection site pain: mild discomfort at the venipuncture site.
  • Nausea: transient feeling of queasiness.
  • Flushing or warmth: brief sensation of heat.
  • Headache: mild to moderate intensity.
  • Dizziness: temporary light‑headedness.
  • Mild allergic reaction: rash or itching.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic response requiring immediate medical attention.
  • Significant radiation‑induced tissue injury: unlikely but possible with high cumulative doses.
  • Severe hypotension: marked drop in blood pressure post‑injection.
  • Cardiac arrhythmia: irregular heart rhythm in susceptible individuals.
  • Persistent vomiting: prolonged emesis requiring intervention.

Precautions & Warnings

Use of Natriumfluorid (F-18) requires careful consideration of patient factors and handling procedures.

  • Pregnancy: safety unknown; avoid unless essential for maternal care.
  • Breastfeeding: unknown safety; weigh potential risks before use.
  • Renal impairment: monitor closely as fluoride is renally cleared.
  • Allergy history: assess for hypersensitivity to fluoride compounds.
  • Radiation safety: follow local regulations for handling and disposal of radioactive material.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Potential interactions may affect tracer distribution or radiation exposure.

Major Interactions (Avoid)

  • Calcium supplements or high‑calcium diet: can reduce tracer uptake in bone.
  • Concurrent administration of other radiopharmaceuticals: may cause overlapping radiation dose.

Moderate Interactions (Monitor Closely)

  • Bisphosphonates or other bone‑active agents: may alter fluoride incorporation.
  • Renal‑affecting drugs (e.g., NSAIDs, ACE inhibitors): may modify clearance.
  • Iodinated contrast agents used in CT: could interfere with PET image interpretation.
  • Anticonvulsants influencing bone metabolism: monitor imaging results.

Frequently Asked Questions

Natriumfluorid (F-18) Life Radiopharma is a diagnostic radiopharmaceutical used in positron emission tomography (PET) to image bone metabolism. It helps clinicians detect skeletal metastases, assess bone turnover, and stage cancers that involve the skeleton.

Sodium fluoride (18F) releases fluoride ions that rapidly bind to the hydroxyapatite crystals in bone, replacing hydroxyl groups. The incorporated radioactive fluorine emits positrons, which are captured by the PET scanner to produce high‑resolution images of bone remodeling activity.

The administered activity is determined by the prescribing physician or nuclear medicine specialist based on patient weight, imaging protocol, and regulatory guidelines. Exact dosing is individualized and should follow the institution’s standard operating procedures.

Safety data for pregnancy and breastfeeding are limited, and the product is classified as having an unknown risk. It should only be used when the potential diagnostic benefit outweighs any possible risk to the fetus or infant, and after careful consultation with a specialist.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Sodium fluoride (18F) offers higher bone uptake and faster blood clearance than older tracers such as 99mTc‑MDP used in SPECT. Compared with 18F‑NaF, it provides superior image resolution and quantification, making it a preferred choice for detailed assessment of skeletal disease.

The product must be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. It should be handled in a radiation‑controlled area using appropriate shielding and personal protective equipment, and used within the specified shelf‑life after elution.

The radiopharmaceutical is administered intravenously as a sterile solution. After injection, a short uptake period (typically 30–60 minutes) is observed before the patient is positioned in the PET scanner for image acquisition.

Serious risks include rare severe allergic reactions (anaphylaxis), significant radiation‑induced tissue injury with high cumulative exposure, and rare cardiovascular events such as severe hypotension or arrhythmia. Immediate medical attention is required if any of these occur.

Patients with known hypersensitivity to fluoride compounds, those who are pregnant or breastfeeding unless absolutely necessary, and individuals with severe renal impairment where fluoride clearance is compromised should avoid this tracer unless a risk‑benefit assessment justifies its use.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sodium Fluoride (18f)

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT